Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Seasonal variability of lung function and Asthma Quality of Life Questionnaire Scores in adults with uncontrolled asthma.

N Bauer R, Yang X, L Staton T, Olsson J, Holweg CTJ, R Arron J, Matthews JG, Choy DF.

BMJ Open Respir Res. 2019 Nov 11;6(1):e000406. doi: 10.1136/bmjresp-2019-000406. eCollection 2019.

2.

Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study.

Busby J, Holweg CTJ, Chai A, Bradding P, Cai F, Chaudhuri R, Mansur AH, Lordan JL, Matthews JG, Menzies-Gow A, Niven R, Staton T, Heaney LG.

Thorax. 2019 Aug;74(8):806-809. doi: 10.1136/thoraxjnl-2018-212709. Epub 2019 Apr 2.

PMID:
30940770
3.

Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis.

Rhee RL, Holweg CTJ, Wong K, Cuthbertson D, Carette S, Khalidi NA, Koening CL, Langford CA, McAlear CA, Monach PA, Moreland LW, Pagnoux C, Seo P, Specks U, Sreih AG, Ytterberg SR, Merkel PA; Vasculitis Clinical Research Consortium.

PLoS One. 2018 Oct 11;13(10):e0205768. doi: 10.1371/journal.pone.0205768. eCollection 2018.

4.

Change in biomarkers of type-2 inflammation following severe exacerbations of asthma.

Semprini R, Shortt N, Ebmeier S, Semprini A, Varughese R, Holweg CTJ, Matthews JG, Fingleton J, Weatherall M, Beasley R, Braithwaite I.

Thorax. 2019 Jan;74(1):95-98. doi: 10.1136/thoraxjnl-2018-211657. Epub 2018 Jul 18.

PMID:
30021810
5.

U-BIOPRED: evaluation of the value of a public-private partnership to industry.

Riley JH, Erpenbeck VJ, Matthews JG, Holweg CTJ, Compton C, Seibold W, Higenbottam T, Wagers S, Rowe A, Myles D; Industry Representatives of the U-BIOPRED Study Group.

Drug Discov Today. 2018 Sep;23(9):1622-1634. doi: 10.1016/j.drudis.2018.06.015. Epub 2018 Jun 21. Review.

PMID:
29936248
6.

Serum periostin does not reflect type 2-driven inflammation in COPD.

Carpaij OA, Muntinghe FOW, Wagenaar MB, Habing JW, Timens W, Kerstjens HAM, Nawijn MC, Kunz LIZ, Hiemstra PS, Tew GW, Holweg CTJ, Brandsma CA, van den Berge M.

Respir Res. 2018 Jun 7;19(1):112. doi: 10.1186/s12931-018-0818-8.

7.

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.

Korenblat P, Kerwin E, Leshchenko I, Yen K, Holweg CTJ, Anzures-Cabrera J, Martin C, Putnam WS, Governale L, Olsson J, Matthews JG.

Respir Med. 2018 Jan;134:143-149. doi: 10.1016/j.rmed.2017.12.006. Epub 2017 Dec 13.

8.

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial.

Hanratty CE, Matthews JG, Arron JR, Choy DF, Pavord ID, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Djukanovic R, Gallagher N, Fowler SJ, Hardman TC, Harrison T, Holweg CT, Howarth PH, Lordan J, Mansur AH, Menzies-Gow A, Mosesova S, Niven RM, Robinson DS, Shaw DE, Walker S, Woodcock A, Heaney LG; RASP-UK (Refractory Asthma Stratification Programme) Consortium.

Trials. 2018 Jan 4;19(1):5. doi: 10.1186/s13063-017-2384-7.

9.

Interleukin-13 in Asthma and Other Eosinophilic Disorders.

Doran E, Cai F, Holweg CTJ, Wong K, Brumm J, Arron JR.

Front Med (Lausanne). 2017 Sep 19;4:139. doi: 10.3389/fmed.2017.00139. eCollection 2017.

10.

Serum periostin, IgE, and SE-IgE can be used as biomarkers to identify moderate to severe chronic rhinosinusitis with nasal polyps.

Jonstam K, Westman M, Holtappels G, Holweg CTJ, Bachert C.

J Allergy Clin Immunol. 2017 Dec;140(6):1705-1708.e3. doi: 10.1016/j.jaci.2017.07.031. Epub 2017 Sep 1. No abstract available.

PMID:
28870464
11.

Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.

Zhu R, Zheng Y, Dirks NL, Vadhavkar S, Jin JY, Peng K, Holweg CTJ, Olsson J, Matthews JG, Putnam WS.

Pulm Pharmacol Ther. 2017 Oct;46:88-98. doi: 10.1016/j.pupt.2017.08.010. Epub 2017 Aug 24.

12.

High density lipoproteins and type 2 inflammatory biomarkers are negatively correlated in atopic asthmatics.

Barochia AV, Gordon EM, Kaler M, Cuento RA, Theard P, Figueroa DM, Yao X, Weir NA, Sampson ML, Stylianou M, Choy DF, Holweg CTJ, Remaley AT, Levine SJ.

J Lipid Res. 2017 Aug;58(8):1713-1721. doi: 10.1194/jlr.P077776. Epub 2017 Jun 27.

13.

Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab.

Staton TL, Arron JR, Olsson J, Holweg CTJ, Matthews JG, Choy DF.

J Allergy Clin Immunol. 2017 May;139(5):1682-1684.e3. doi: 10.1016/j.jaci.2017.01.028. Epub 2017 Feb 24. No abstract available.

PMID:
28238745
14.

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.

Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG.

Lancet Respir Med. 2016 Oct;4(10):781-796. doi: 10.1016/S2213-2600(16)30265-X. Epub 2016 Sep 5.

PMID:
27616196
15.

Relationships among aeroallergen sensitization, peripheral blood eosinophils, and periostin in pediatric asthma development.

Anderson HM, Lemanske RF Jr, Arron JR, Holweg CTJ, Rajamanickam V, Gangnon RE, Gern JE, Jackson DJ.

J Allergy Clin Immunol. 2017 Mar;139(3):790-796. doi: 10.1016/j.jaci.2016.05.033. Epub 2016 Jul 5.

16.

Periostin levels and eosinophilic inflammation in poorly-controlled asthma.

Simpson JL, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, Jia G, Holweg CT, Gibson PG.

BMC Pulm Med. 2016 Apr 30;16(1):67. doi: 10.1186/s12890-016-0230-4.

17.

Serum periostin is associated with type 2 immunity in severe asthma.

Johansson MW, Evans MD, Crisafi GM, Holweg CTJ, Matthews JG, Jarjour NN.

J Allergy Clin Immunol. 2016 Jun;137(6):1904-1907.e2. doi: 10.1016/j.jaci.2015.12.1346. Epub 2016 Apr 6. No abstract available.

18.

Roles of Periostin in Respiratory Disorders.

Izuhara K, Conway SJ, Moore BB, Matsumoto H, Holweg CT, Matthews JG, Arron JR.

Am J Respir Crit Care Med. 2016 May 1;193(9):949-56. doi: 10.1164/rccm.201510-2032PP. Review.

19.

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K.

Thorax. 2015 Aug;70(8):748-56. doi: 10.1136/thoraxjnl-2014-206719. Epub 2015 May 22.

20.

Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.

Dennis G Jr, Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, Haverty PM, Gilbert H, Lin WY, Diehl L, Fischer S, Song A, Musselman D, Klearman M, Gabay C, Kavanaugh A, Endres J, Fox DA, Martin F, Townsend MJ.

Arthritis Res Ther. 2014;16(2):R90. Epub 2014 Apr 30.

21.

The role of periostin in tissue remodeling across health and disease.

Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, Arron JR, Holweg CT, Kudo A.

Cell Mol Life Sci. 2014 Apr;71(7):1279-88. doi: 10.1007/s00018-013-1494-y. Epub 2013 Oct 22. Review.

22.

Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab.

Hogan VE, Holweg CT, Choy DF, Kummerfeld SK, Hackney JA, Teng YK, Townsend MJ, van Laar JM.

Ann Rheum Dis. 2012 Nov;71(11):1888-94. doi: 10.1136/annrheumdis-2011-201115. Epub 2012 Jun 26.

PMID:
22736099
23.

Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.

Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ.

Arthritis Rheum. 2011 Dec;63(12):3681-91. doi: 10.1002/art.30596.

24.

A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis.

Owczarczyk K, Lal P, Abbas AR, Wolslegel K, Holweg CT, Dummer W, Kelman A, Brunetta P, Lewin-Koh N, Sorani M, Leong D, Fielder P, Yocum D, Ho C, Ortmann W, Townsend MJ, Behrens TW.

Sci Transl Med. 2011 Sep 21;3(101):101ra92. doi: 10.1126/scitranslmed.3002432.

25.

Identification and classification of acute cardiac rejection by intragraft transcriptional profiling.

Holweg CT, Potena L, Luikart H, Yu T, Berry GJ, Cooke JP, Valantine HA, Mocarski ES.

Circulation. 2011 May 24;123(20):2236-43. doi: 10.1161/CIRCULATIONAHA.109.913921. Epub 2011 May 9.

26.

Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis.

Potena L, Holweg CT, Vana ML, Bashyam L, Rajamani J, McCormick AL, Cooke JP, Valantine HA, Mocarski ES.

J Clin Microbiol. 2007 Jun;45(6):1804-10. Epub 2007 Apr 4. Erratum in: J Clin Microbiol. 2008 Dec;46(12):4121.

27.

The impact of transforming growth factor-beta1 gene polymorphism on end-stage renal failure after heart transplantation.

van de Wetering J, Weimar CH, Balk AH, Roodnat JI, Holweg CT, Baan CC, van Domburg RT, Weimar W.

Transplantation. 2006 Dec 27;82(12):1744-8.

PMID:
17198270
28.

Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.

Potena L, Holweg CT, Chin C, Luikart H, Weisshaar D, Narasimhan B, Fearon WF, Lewis DB, Cooke JP, Mocarski ES, Valantine HA.

Transplantation. 2006 Aug 15;82(3):398-405.

PMID:
16906040
29.

Functional heme oxygenase-1 promoter polymorphism in relation to heart failure and cardiac transplantation.

Holweg CT, Balk AH, Uitterlinden AG, Niesters HG, Maat LP, Weimar W, Baan CC.

J Heart Lung Transplant. 2005 Apr;24(4):493-7.

PMID:
15797755
30.

Intragraft heme oxygenase-1 and coronary artery disease after heart transplantation.

Holweg CT, Balk AH, Snaathorst J, van den Engel S, Niesters HG, Maat AW, Zondervan PE, Weimar W, Baan CC.

Transpl Immunol. 2004 Dec;13(4):265-72.

PMID:
15589739
31.

Clinical impact of cytokine gene polymorphisms in heart and lung transplantation.

Holweg CT, Weimar W, Uitterlinden AG, Baan CC.

J Heart Lung Transplant. 2004 Sep;23(9):1017-26. Review. No abstract available.

PMID:
15454166
32.

Recipient gene polymorphisms in the Th-1 cytokines IL-2 and IFN-gamma in relation to acute rejection and graft vascular disease after clinical heart transplantation.

Holweg CT, Peeters AM, Balk AH, Uitterlinden AG, Niesters HG, Maat AP, Weimar W, Baan CC.

Transpl Immunol. 2003 Jan-Mar;11(1):121-7.

PMID:
12727483
33.

Effect of HLA-DR matching on acute rejection after clinical heart transplantation might be influenced by an IL-2 gene polymorphism.

Holweg CT, Peeters AM, Balk AH, Uitterlinden AG, Niesters HG, Maat AP, Weimar W, Baan CC.

Transplantation. 2002 Apr 27;73(8):1353-6.

PMID:
11981437
34.

TGF-beta1 gene polymorphisms in patients with end-stage heart failure.

Holweg CT, Baan CC, Niesters HG, Vantrimpont PJ, Mulder PG, Maat AP, Weimar W, Balk AH.

J Heart Lung Transplant. 2001 Sep;20(9):979-84.

PMID:
11557193
35.

The transforming growth factor-beta1 codon 10 gene polymorphism and accelerated graft vascular disease after clinical heart transplantation.

Holweg CT, Baan CC, Balk AH, Niesters HG, Maat AP, Mulder PM, Weimar W.

Transplantation. 2001 May 27;71(10):1463-7.

PMID:
11391236
36.

Cytokine profiles as marker for graft vascular disease after clinical heart transplantation.

van Besouw NM, Baan CC, Holweg CT, de Groot-Kruseman HA, Peeters AM, Balk AH, Weimar W.

Ann Transplant. 2000;5(2):61-7. No abstract available.

PMID:
11217209
37.

Renal failure after clinical heart transplantation is associated with the TGF-beta 1 codon 10 gene polymorphism.

Baan CC, Balk AH, Holweg CT, van Riemsdijk IC, Maat LP, Vantrimpont PJ, Niesters HG, Weimar W.

J Heart Lung Transplant. 2000 Sep;19(9):866-72.

PMID:
11008076
38.

Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection.

Baan CC, van Gelder T, Balk AH, Knoop CJ, Holweg CT, Maat LP, Weimar W.

Transplantation. 2000 Feb 15;69(3):331-6.

PMID:
10706038
39.

The macrophage-derived T-cell growth factor interleukin-15 is present in interleukin-2-independent rejection after clinical heart and liver transplantation.

Baan CC, Knoop CJ, Holweg CT, van Gelder T, Metselaar HJ, Niesters HG, Zondervan PE, Balk AH, Weimar W.

Transplant Proc. 1999 Nov;31(7):2726-8. No abstract available.

PMID:
10578266
40.

Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation.

Baan CC, Knoop CJ, van Gelder T, Holweg CT, Niesters HG, Smeets TJ, van der Ham F, Zondervan PE, Maat LP, Balk AH, Weimar W.

Transplantation. 1999 Mar 27;67(6):870-6.

PMID:
10199736
41.

Contribution of the inflammatory response to cardiac allograft rejection: histopathologic analysis of serial endomyocardial biopsies.

Baan CC, Knoop CJ, van Gelder T, van der Ham F, Zondervan PE, Holweg CT, Mochtar B, Balk AH, Weimar W.

Transplant Proc. 1998 Jun;30(4):1104-6. No abstract available.

PMID:
9636448
42.

The nature of acute rejection is associated with development of graft vascular disease after clinical heart transplantation.

Baan CC, Holweg CT, Niesters HG, van Gelder T, Mol WM, Zondervan PE, Mochtar B, Balk AH, Weimar W.

J Heart Lung Transplant. 1998 Apr;17(4):363-73.

PMID:
9588581
43.

Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans.

van Gelder T, Baan CC, Balk AH, Knoop CJ, Holweg CT, van der Meer P, Mochtar B, Zondervan PE, Niesters HG, Weimar W.

Transplantation. 1998 Feb 15;65(3):405-10.

PMID:
9484761
44.

Intragraft cytokine and growth factor mRNA expression in relation to graft vascular disease after heart transplantation.

Baan CC, Holweg CT, Niesters HG, van Gelder T, Mol WM, Mochtar B, Balk AH, Weimar W.

Transplant Proc. 1997 Sep;29(6):2535-6. No abstract available.

PMID:
9290730

Supplemental Content

Loading ...
Support Center